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Letter to the Editor:
Primitive Neuroectodermal Kidney Tumor
To the Editor: Primitive neuroectodermal tumors
(PNET) and Ewing sarcoma (ES) belong to a group
of neoplasms de®ned by neuroectodermal differentiation
and a characteristic cytogenetic translocation, t(11;22)
(q24;q12) or gene rearrangements between chromosomes
21 and 22 [1]. They are generally aggressive tumors that
present as metastatic disease in nearly 50% of the cases.
ES is frequently a bone disease, whereas PNET can occur
in bones, soft tissues, or any other site. Renal PNETs
are extremely rare, with only a few cases reported [2].
We here record an adult with renal PNET and bone
metastases at diagnosis. Because these tumor can also be
found in children [3] our experience may therefore be
helpful to pediatric oncologists.
A 38-year-old male with no medical antecedents
consulted in November 1997 with a 6-month abdominal
history of pain in the upper and mid-left quadrants.
Physical examination showed what appeared to be a
painful, enlarged spleen. Computed tomography (CT)
and magnetic resonance imaging (MRI) revealed a
120 120-mm tumor mass involving the left kidney. A
technetium bone scan showed an enhanced, in®ltrative
vertebral lesion (T-10). A radical left nephrectomy was
performed on 12/17/97; pathologic examination discov-
ered a renal PNET, con®rmed by the detection of the
translocation t(11;22) in tumor cells.
After surgery, external beam irradiation was delivered
to the tumor bed and bone lesion (50 Gy, 180 cGy ®ve
days each week). Simultaneously, systemic EVAIA
chemotherapy was started (etoposide 120 mg/m2 on days
1±3, vincristine 2 mg total dose on day 1, doxorubicin
20 mg/m2 on days 1±3 alternating in cycles with
dactinomycin 0.5 mg/m2 on days 1±3, and ifosfamide
3,000 mg/m2 on days 1±3). The patient received 9 cycles.
On November 1998, he underwent high-dose chemo-
therapy (carboplatin, etoposide, and cyclophosphamide)
and autologous peripheral blood stem-cell transplantation
as consolidation of a complete response.
On March 1999, the patient was readmitted with
left shoulder pain and multiple bone lesions were found.
He then received palliative irradiation and salvage
chemotherapy with high-dose ifosfamide and doxorubi-
cin. The treatment was stopped after 4 cycles due to
myelotoxicity and absence of clinical response; three
months later he developed dyspnea. A CT scan revealed
multiple lung and liver metastases, with pleural effusions.
Shortly after, he developed spinal cord compression with
paraplegia and died from tumor progression.
Genito-urinary tract PNETs are rare, with isolated
cases reported in children as well as adults of renal,
uterine, and epididymal involvement [2,3]. Almost 30%
of all newly diagnosed cases present with distant
metastases, thus showing the biologic aggressiveness of
the disease. The most frequent metastatic sites are the
lung, bone, and bone marrow.
This case is representative of the clinical course of
metastatic PNET with poor prognostic factors (bulky
primary disease and bone lesions). With aggressive,
combined modality treatment (surgery, irradiation, che-
motherapy, and autotransplant), a complete response was
achieved. However, the patient soon developed a systemic
relapse with a poor response to salvage therapy. We
conclude that patients with the Ewing family of tumors and
poor prognostic factors must be treated with curative intent,
even when the primary site is atypical.
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